Overcome the challenges of PMS2 variant calling with Devyser LynchFAP – our new NGS solution
Devyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Targeted gene sequencing for hereditary breast and ovarian cancers can help save lives by detecting DNA mutations that increase a person’s cancer risk.
Quick and easy identification of breast and ovarian cancer predisposition variants can make a vast difference to women at risk. Our germline mutation analysis test kits identify women with elevated risk of developing breast and ovarian cancer and who may benefit from risk-reducing strategies.
“With the introduction of NGS, the number of detected sequence variants in BRCA1 and BRCA2 is increasing fast.”
Devyser Insight
Breast cancer is the most common form of cancer in women and the leading cause of cancer-related death. Ovarian cancer is the deadliest gynecological cancer, with a five-year survival rate of 45 percent.
In both diseases, family history can be a significant risk factor. Next-generation DNA testing can detect hereditary breast and ovarian cancer risk.
Diagnostic tests identify women with elevated risk who may benefit from risk-reducing strategies such as prophylactic surgery, hormone replacement therapy or targeted treatment using PARP inhibitors such as LynparzaTM (olaparib).
Devyser BRCA and Devyser HBOC kits are rapid, targeted NGS library preparation assays that detect variants in BRCA1, BRCA2 and 12 additional genes where mutations are known to significantly increase the risk of developing breast and ovarian cancer.
The tests are fast and easy to use. The CE-IVD solution is end-to-end – from sample to result. This saves time, is easy to implement and is simple to replicate.
A short handling time of 45 minutes increases lab productivity, freeing up technicians to run more tests in a given time frame.
The kits use somatic mutation analysis to detect women who may benefit from targeted treatments.
Our Devyser HBOC kit can also be used as a standalone follow-up after negative BRCA testing with Devyser BRCA.
Fast and effective test data analysis is crucial to achieving accurate outcomes and efficient workflows.
Dedicated software in our products makes analyzing test results quick, easy and trouble-free. For lab personnel, this means a streamlined end-to-end process with unmatched reliability and transparency.
Find out moreNews | October 29, 2024
Devyser seeks to secure FDA approval for NGS test for kidney transplant monitoringNews | October 28, 2024
Devyser Compact achieves Class III approval in ChinaDevyser LynchFAP is the latest addition to Devyser’s expanding hereditary cancer screening...
Read More
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA...
Read More
As a lab manager, you know the importance of streamlining workflows to maximize productivity and...
Read More
Do you know a man who has participated at least once in “Movember”? Every year, thousands of men...
Read More